The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.
Analyst Commentary
Recent research notes on Haemonetics reflect a mix of optimism and caution, highlighting both the potential for recovery and ongoing operational challenges affecting the company's valuation and growth outlook.
Bullish Takeaways- Several analysts maintain Buy or Outperform ratings. They emphasize that Haemonetics is still viewed as an attractive and undervalued asset despite recent setbacks.
- Q1 earnings results showcased resilience in the Plasma segment, which exceeded expectations and provided an important offset to weaker areas.
- Management has reiterated guidance for 2026, signaling confidence in the company's medium-term growth trajectory even after a turbulent quarter.
- Bullish analysts argue that operational issues in Interventional Technologies are seen as fixable. This suggests the potential for improved execution over time.
- Bearish analysts express concern over sales execution and ongoing weakness in the Interventional Technologies (IVT) segment, particularly after a challenging Q2 and deterioration in associated business lines.
- Recent downgrades and lowered price targets reflect diminished confidence in management's ability to swiftly address execution risks. This has also led to the removal of shares from some analysts' top picks lists.
- Lower price/equity multiples and further reductions to price targets underscore concern about near-term margin pressures and muted expectations for outsized earnings beats until commercial strategy in IVT is reconfigured.
- Mixed results across segments, with Hospital and IVT performance lagging behind Plasma, have cast uncertainty over the company's ability to deliver consistent, broad-based growth in the immediate future.
What's in the News
- Haemonetics reaffirmed its full year 2026 revenue guidance, projecting a 3% to 6% reported revenue decline (Key Developments).
- Between March 30 and April 8, 2025, the company completed the repurchase of 4,392,179 shares, representing 8.68% of shares for $300 million, following the buyback announced in August 2022 (Key Developments).
- From April 1 to June 28, 2025, no additional shares were repurchased under the May 2025 buyback plan (Key Developments).
Valuation Changes
- Consensus Analyst Price Target (Fair Value): Decreased slightly from $78.64 to $76.91.
- Discount Rate: Increased marginally from 8.42% to 8.47%. This indicates a modest reassessment of risk.
- Revenue Growth: Decreased from 2.60% to 2.46%. This reflects more muted future growth expectations.
- Net Profit Margin: Improved slightly from 17.74% to 17.91%.
- Future P/E Ratio: Declined from 16.32x to 15.90x. This suggests a more conservative valuation of expected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.